S
Sylva H. Collins
Researcher at Cubist Pharmaceuticals
Publications - 2
Citations - 412
Sylva H. Collins is an academic researcher from Cubist Pharmaceuticals. The author has contributed to research in topics: Drug resistance & Tazobactam. The author has an hindex of 2, co-authored 2 publications receiving 335 citations.
Papers
More filters
Journal ArticleDOI
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph S. Solomkin,Ellie Hershberger,Benjamin Miller,Myra Popejoy,Ian Friedland,Judith N. Steenbergen,Minjung Yoon,Sylva H. Collins,Guojun Yuan,Philip S. Barie,Christian Eckmann +10 more
TL;DR: This phase 3 trial compared ceftolozane/tazobactam plus metronidazole vs meropenem for the treatment of complicated intra-abdominal infections with high rates of presumed microbiological eradication of Enterobacteriaceae and Pseudomonas aeruginosa.
Journal ArticleDOI
Risk Estimation for Recurrent Clostridium Difficile Infection Based on Clinical Factors
TL;DR: A simple/practical scoring rule (logistic regression model) for recurrent CDI is developed using data from 2 large phase 3 clinical trials and may be useful for treatment decision.